Table 3.
Rates of adverse events and compliance of each therapy group.
| Variables | TBQT (n = 160) | TAD (n = 159) | BQT (n = 149) | p |
|---|---|---|---|---|
| Adverse events | 33 (20.6) | 24 (15.1) | 37 (24.8) | 0.472 |
| Mild | 25 | 21 | 28 | |
| Moderate | 8 | 3 | 9 | |
| Severe | 0 | 0 | 0 | |
| Adverse events | ||||
| Dizziness | 4 (2.5) | 2 (1.3) | 4 (2.7) | 0.184 |
| Abdominal pain | 5 (3.1) | 2 (1.3) | 6 (4.0) | 0.318 |
| Abdominal distention | 5 (3.1) | 6 (3.8) | 8 (5.4) | 0.579 |
| Nausea | 6 (3.8) | 5 (3.1) | 6 (4.0) | 0.241 |
| Diarrhea | 3 (1.9) | 4 (2.5) | 5 (3.4) | 0.427 |
| Bitter taste of mouth | 8 (5.0) | 2 (1.3) | 7 (4.7) | 0.273 |
| Others | 2 (1.3) | 3 (1.9) | 1 (0.7) | 0.541 |
| Treatment compliance | 156 (97.5) | 156 (98.1) | 145 (97.3) | 0.709 |
Data are expressed as number (percentage) of patients. Treatment compliance was defined as the proportion of patients who consumed at least 85% of study drugs. AEs, adverse events; BQT, rabeprazole 10 mg twice daily, compound bismuth aluminate granules 2.6 g thrice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily; TAD, tegoprazan 50 mg twice daily, amoxicillin 1 g thrice daily; TBQT, tegoprazan 50 mg twice daily, compound bismuth aluminate granules 2.6 g thrice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily.